Mage-3 Peptide
Malignant Melanoma
M.D. Anderson Cancer Centerprotein_peptidePhase 2Dormant
CCC
49/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 34/ 100
- Competitive Position
- 81/ 100
Competitive context
450 Active assets in the Malignant Melanoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Gm-Csf Ultimovacs ASA | Phase 4 | BBB |
Sargramostim Mayo Clinic | Phase 3 | BBB |
Cediranib M.D. Anderson Cancer Center | Phase 3 | BBB |
Ifa Craig L Slingluff, Jr | Phase 2 | BB |
Tebentafusp Immunocore Ltd | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Mage-3 Peptide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →